Economic Performance - In the first quarter, Chongzuo's GDP reached 33.509 billion yuan, with a year-on-year growth of 7.3%, ranking second in the region [1] - The primary industry grew by 4.5%, the secondary industry by 7.7%, and the tertiary industry by 7.3%, indicating a balanced economic recovery [1] Project Development - Chongzuo held a major project commencement and completion ceremony in March, featuring 71 projects with a total investment of 16.4 billion yuan, including 44 new projects worth 14.4 billion yuan and 27 completed projects worth 2 billion yuan [2] Service and Support for Enterprises - The Chongzuo Work Team has been actively involved in supporting project construction, focusing on land use and other issues to facilitate the progress of key projects like the Longma Control Group's high-end equipment manufacturing base [3] - The team has also helped various enterprises, including Southern Manganese Group and China-ASEAN Nanning Airport Fusui Economic Zone, to resolve construction-related challenges, thereby improving the business environment [3] Addressing Business Challenges - The Chongzuo Work Team has addressed issues faced by local enterprises, such as the case of Guangxi Huatiangbao, which faced production challenges due to regulatory changes. The team facilitated the approval for cross-province production licenses [4] - By the end of April, the team had collected 110 feedback issues from enterprises, resolving 97 of them, achieving an 88.18% resolution rate [4] Technological Empowerment - Chongzuo is focusing on integrating technology into industry, with 46 smart manufacturing demonstration factories established in the first quarter and 26 enterprises recognized in national and regional smart manufacturing collections [6] - The Work Team has been instrumental in promoting technological innovation, including the establishment of key laboratories and partnerships to enhance the sugar industry through data-driven services [6]

Core Viewpoint - The safety concerns surrounding traditional Chinese medicine (TCM) injection solutions, particularly the case of a patient who died after receiving a Schisandra injection, have reignited discussions about the risks associated with these products and the need for improved regulatory oversight [1][3][11]. Industry Overview - The market for TCM injection solutions has seen a significant decline, with total market size dropping from 831.3 billion in 2015 to 479.8 billion in 2023, a nearly 50% reduction [7]. - Major companies in the sector, such as ST Longjin and Dali Pharmaceutical, have faced severe financial difficulties, with ST Longjin's revenue declining by 36.19% to 0.48 billion in 2024 [8][9]. - Despite the challenges, some companies remain optimistic about the potential for TCM injections, with predictions that products like Kanyuan Pharmaceutical's Hot Toxic Ning injection could benefit from increased insurance coverage and expanded indications [5]. Regulatory Environment - The National Medical Products Administration (NMPA) has been actively revising the instructions for TCM injections, adding warnings about severe allergic reactions and requiring monitoring after administration [11][12]. - Recent changes in the 2023 medical insurance drug directory have relaxed some payment restrictions on TCM injections, allowing for broader use in clinical settings [13][14]. - However, the existing risk management system still has shortcomings, such as delayed implementation of revised instructions and insufficient training for medical staff on proper medication use [12]. Safety Concerns - Reports indicate that adverse reactions to TCM injections, particularly allergic reactions, are common, especially among older patients [3][6]. - The complexity of TCM injection formulations and the potential for contamination during production contribute to safety risks [6][10]. - The industry faces ongoing scrutiny regarding the quality control of TCM injections, with calls for stricter regulations and better monitoring of adverse reactions [10][15]. Future Outlook - The TCM injection industry must navigate its way out of the current downturn by focusing on product upgrades, regulatory compliance, and enhancing safety monitoring systems [10][16]. - Companies are encouraged to adopt modern scientific methods to assess the safety of TCM injections and to implement stricter quality control measures [16].